A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission

Saiko Kurosawa; Takuhiro Yamaguchi; Shuichi Miyawaki; Naoyuki Uchida; Heiwa Kanamori; Kensuke Usuki; Takuya Yamashita; Masato Watanabe; Kazuaki Yakushiji; Shingo Yano; Yuichiro Nawa; Jun Taguchi; Jin Takeuchi; Junji Tomiyama; Yuko Nakamura; Ikuo Miura; Yoshinobu Kanda; Yoichi Takaue; Takahiro Fukuda

doi:10.1182/blood-2010-05-285502

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission

Saiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, Naoyuki Uchida, Heiwa Kanamori, Kensuke Usuki, Takuya Yamashita, Masato Watanabe, Kazuaki Yakushiji, Shingo Yano, Yuichiro Nawa, Jun Taguchi, Jin Takeuchi, Junji Tomiyama, Yuko Nakamura, Ikuo Miura, Yoshinobu Kanda, Yoichi Takaue, Takahiro Fukuda

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

Various prospective trials have been performed to assess the roles of allogeneic hematopoietic cell transplantation (allo-HCT) and chemotherapy in patients with acute myeloid leukemia (AML) in first complete remission (CR1). However, the results have not always been consistent, and there has been a limited evaluation of quality of life (QOL) in these postremission strategies. We performed a Markov decision analysis that enabled us to compare survival outcomes with a QOL evaluation using a database of 2029 adult AML patients who achieved CR1. The Markov decision model compared 2 strategies: allo-HCT or chemotherapy in CR1. Patients who had intermediate- or unfavorable-risk AML had a longer life expectancy when they received allo-HCT in CR1 than patients treated with chemotherapy alone. Likewise, patients who had a suitable related donor who received allo-HCT in CR1 had a longer life expectancy. The life expectancy was shortened to a greater degree by adjustment for QOL in the allo-HCT group. Nevertheless, QOLadjusted life expectancies in most of the subgroups remained longer in the allo-HCT group than in the chemotherapy group. Our results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allo-HCT in CR1.

Original language	English
Pages (from-to)	2113-2120
Number of pages	8
Journal	Blood
Volume	117
Issue number	7
DOIs	https://doi.org/10.1182/blood-2010-05-285502
Publication status	Published - 2011 Feb 17
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2010-05-285502

Cite this

Kurosawa, S., Yamaguchi, T., Miyawaki, S., Uchida, N., Kanamori, H., Usuki, K., Yamashita, T., Watanabe, M., Yakushiji, K., Yano, S., Nawa, Y., Taguchi, J., Takeuchi, J., Tomiyama, J., Nakamura, Y., Miura, I., Kanda, Y., Takaue, Y., & Fukuda, T. (2011). A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood, 117(7), 2113-2120. https://doi.org/10.1182/blood-2010-05-285502

Kurosawa, S, Yamaguchi, T, Miyawaki, S, Uchida, N, Kanamori, H, Usuki, K, Yamashita, T, Watanabe, M, Yakushiji, K, Yano, S, Nawa, Y, Taguchi, J, Takeuchi, J, Tomiyama, J, Nakamura, Y, Miura, I, Kanda, Y, Takaue, Y & Fukuda, T 2011, 'A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission', Blood, vol. 117, no. 7, pp. 2113-2120. https://doi.org/10.1182/blood-2010-05-285502

@article{10cb4ea301424793ad0fc1d629ac2246,

title = "A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission",

abstract = "Various prospective trials have been performed to assess the roles of allogeneic hematopoietic cell transplantation (allo-HCT) and chemotherapy in patients with acute myeloid leukemia (AML) in first complete remission (CR1). However, the results have not always been consistent, and there has been a limited evaluation of quality of life (QOL) in these postremission strategies. We performed a Markov decision analysis that enabled us to compare survival outcomes with a QOL evaluation using a database of 2029 adult AML patients who achieved CR1. The Markov decision model compared 2 strategies: allo-HCT or chemotherapy in CR1. Patients who had intermediate- or unfavorable-risk AML had a longer life expectancy when they received allo-HCT in CR1 than patients treated with chemotherapy alone. Likewise, patients who had a suitable related donor who received allo-HCT in CR1 had a longer life expectancy. The life expectancy was shortened to a greater degree by adjustment for QOL in the allo-HCT group. Nevertheless, QOLadjusted life expectancies in most of the subgroups remained longer in the allo-HCT group than in the chemotherapy group. Our results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allo-HCT in CR1.",

author = "Saiko Kurosawa and Takuhiro Yamaguchi and Shuichi Miyawaki and Naoyuki Uchida and Heiwa Kanamori and Kensuke Usuki and Takuya Yamashita and Masato Watanabe and Kazuaki Yakushiji and Shingo Yano and Yuichiro Nawa and Jun Taguchi and Jin Takeuchi and Junji Tomiyama and Yuko Nakamura and Ikuo Miura and Yoshinobu Kanda and Yoichi Takaue and Takahiro Fukuda",

year = "2011",

month = feb,

day = "17",

doi = "10.1182/blood-2010-05-285502",

language = "English",

volume = "117",

pages = "2113--2120",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "7",

}

TY - JOUR

T1 - A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission

AU - Kurosawa, Saiko

AU - Yamaguchi, Takuhiro

AU - Miyawaki, Shuichi

AU - Uchida, Naoyuki

AU - Kanamori, Heiwa

AU - Usuki, Kensuke

AU - Yamashita, Takuya

AU - Watanabe, Masato

AU - Yakushiji, Kazuaki

AU - Yano, Shingo

AU - Nawa, Yuichiro

AU - Taguchi, Jun

AU - Takeuchi, Jin

AU - Tomiyama, Junji

AU - Nakamura, Yuko

AU - Miura, Ikuo

AU - Kanda, Yoshinobu

AU - Takaue, Yoichi

AU - Fukuda, Takahiro

PY - 2011/2/17

Y1 - 2011/2/17

N2 - Various prospective trials have been performed to assess the roles of allogeneic hematopoietic cell transplantation (allo-HCT) and chemotherapy in patients with acute myeloid leukemia (AML) in first complete remission (CR1). However, the results have not always been consistent, and there has been a limited evaluation of quality of life (QOL) in these postremission strategies. We performed a Markov decision analysis that enabled us to compare survival outcomes with a QOL evaluation using a database of 2029 adult AML patients who achieved CR1. The Markov decision model compared 2 strategies: allo-HCT or chemotherapy in CR1. Patients who had intermediate- or unfavorable-risk AML had a longer life expectancy when they received allo-HCT in CR1 than patients treated with chemotherapy alone. Likewise, patients who had a suitable related donor who received allo-HCT in CR1 had a longer life expectancy. The life expectancy was shortened to a greater degree by adjustment for QOL in the allo-HCT group. Nevertheless, QOLadjusted life expectancies in most of the subgroups remained longer in the allo-HCT group than in the chemotherapy group. Our results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allo-HCT in CR1.

AB - Various prospective trials have been performed to assess the roles of allogeneic hematopoietic cell transplantation (allo-HCT) and chemotherapy in patients with acute myeloid leukemia (AML) in first complete remission (CR1). However, the results have not always been consistent, and there has been a limited evaluation of quality of life (QOL) in these postremission strategies. We performed a Markov decision analysis that enabled us to compare survival outcomes with a QOL evaluation using a database of 2029 adult AML patients who achieved CR1. The Markov decision model compared 2 strategies: allo-HCT or chemotherapy in CR1. Patients who had intermediate- or unfavorable-risk AML had a longer life expectancy when they received allo-HCT in CR1 than patients treated with chemotherapy alone. Likewise, patients who had a suitable related donor who received allo-HCT in CR1 had a longer life expectancy. The life expectancy was shortened to a greater degree by adjustment for QOL in the allo-HCT group. Nevertheless, QOLadjusted life expectancies in most of the subgroups remained longer in the allo-HCT group than in the chemotherapy group. Our results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allo-HCT in CR1.

UR - http://www.scopus.com/inward/record.url?scp=79951815193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951815193&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-05-285502

DO - 10.1182/blood-2010-05-285502

M3 - Article

C2 - 21106987

AN - SCOPUS:79951815193

SN - 0006-4971

VL - 117

SP - 2113

EP - 2120

JO - Blood

JF - Blood

IS - 7

ER -

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this